Immunogenicity and safety of an Escherichia coli-produced 9-valent human papillomavirus vaccine (types 6/11/16/18/31/33/45/52/58) in healthy Chinese women aged 20–45 years: a single-center, randomized, observer-blinded, positive controlled phase 2 cl

Authors

Hongxing Pan (ORCID: https://orcid.org/0000-0002-3791-1241)
Jingxin Li (ORCID: https://orcid.org/0000-0002-7033-5151)
Dan Wu (ORCID: https://orcid.org/0000-0003-0415-5467)
Weiwei Han (ORCID: https://orcid.org/0009-0003-3408-6789)
Tao Hong (ORCID: https://orcid.org/0000-0002-2693-8991)
Mingwei Wei
Hongyan Liu
Wenjuan Wang (ORCID: https://orcid.org/0000-0002-6873-4153)
Jing Zhang (ORCID: https://orcid.org/0000-0002-7290-8304)
Huilong Yu

Institutions

Beijing VDJBio (China) (CN)
Jiangsu Provincial Center for Disease Control and Prevention (CN)
Taiwan Centers for Disease Control (TW)
Nanjing Medical University (CN)

Publication Details

Journal: Frontiers in Immunology
Published: 2025-11-14
DOI: https://doi.org/10.3389/fimmu.2025.1706662
Citations: 1
Primary Topic: Cervical Cancer and HPV Research
Type: article
Field-Weighted Citation Impact: 1.35

Funders

National Natural Science Foundation of China

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Immunogenicity and safety of an Escherichia coli-produced 9-valent human papillomavirus vaccine (types 6/11/16/18/31/33/45/52/58) in healthy Chinese women aged 20–45 years: a single-center, randomized, observer-blinded, positive controlled phase 2 cl

Hongxing Pan, Jingxin Li, Dan Wu, Weiwei Han et al.

Nov 14, 2025

1 citations

Frontiers in Immunology

Cervical Cancer and HPV Research

1.35

article

Immunogenicity and safety of an Escherichia coli-produced 9-valent human papillomavirus vaccine (types 6/11/16/18/31/33/45/52/58) in healthy Chinese women aged 20–45 years: a single-center, randomized, observer-blinded, positive controlled phase 2 cl

Hongxing Pan, Jingxin Li, Dan Wu, Weiwei Han, Tao Hong, Mingwei Wei, Hongyan Liu, Wenjuan Wang, Jing Zhang, Huilong Yu

November 14, 2025article en

1 citations

Abstract

No abstract available for this paper.

Frontiers in ImmunologyVol. 16

Beijing VDJBio (China) (CN), Jiangsu Provincial Center for Disease Control and Prevention (CN), Taiwan Centers for Disease Control (TW), Nanjing Medical University (CN)

National Natural Science Foundation of China

Openalex Percentile: Top 14%

Cervical Cancer and HPV Research

1.35

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Immunogenicity and safety of an Escherichia coli-produced 9-valent human papillomavirus vaccine (types 6/11/16/18/31/33/45/52/58) in healthy Chinese women aged 20–45 years: a single-center, randomized, observer-blinded, positive controlled phase 2 cl — Hongxing Pan, Jingxin Li, et al. · Frontiers in Immunology (2025) | TGRS Research Map | TGRS